Full history for every metric is available with a Kvantra account
Inozyme Pharma, Inc. (INZY)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -104 | -107 | |||||
| Net profit | $m | -19 | -56 | -56 | -65 | -71 | -102 | -107 |
| EPS reported | $ | -1.62 | -1.70 | |||||
| Operating cashflow per share | $ | -1.46 | -1.46 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.46 | -1.46 | |||||
| Free cash flow | $m | -92 | -97 | |||||
| Net debt | $m | -67 | -38 | |||||
| Book value equity | $m | 58 | 32 | |||||
| Book value per share | $ | 0.92 | 0.49 | |||||
| Number of shares | m | 62.81 | 64.28 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.01 | 8.12 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.89 | -2.67 | |||||
| EV/EBITDA LTM | x | -1.92 | -2.19 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -58.64% | -40.61% | |||||
| FCF Yield | % | -52.86% | -37.39% | |||||
| Quality | ||||||||
| ROE | % | -176.43% | -102.90% | |||||
| ROIC | % | -99.36% | -99.36% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.96 | -2.06 | |||||
| Net Debt/EBITDA | x | -0.25 | -0.25 | |||||
| EBIT/Net interest | x | 18.72 | 18.72 | |||||
| Net debt/market cap | % | -38.58% | -14.90% | |||||
| Net debt/Equity | x | -1.16 | -1.21 | |||||
| Gross debt/equity | x | 0.81 | 1.48 | |||||
Company overview
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Inozyme Pharma, Inc. (INZY)
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free